Quent Long Short Global Small Cap Fund LP Invests $2.17 Million in AbbVie Inc. $ABBV

Key Points

• Quent Long Short Global Small Cap Fund established a new stake in AbbVie, buying 9,496 shares worth about $2.17 million in Q4, and institutional investors now own roughly 70.2% of the company.
• Company insiders have been selling: EVP Perry Siatis sold 22,381 shares (~$5.15M) and SVP David Purdue sold 5,230 shares (~$1.22M), leaving insiders with just about 0.06% ownership.
• The FDA declined approval of AbbVie’s TrenibotE, issuing a Complete Response Letter over manufacturing issues that could delay cosmetic revenue, even as AbbVie announced a $1.4 billion manufacturing campus in North Carolina to boost capacity.

Quent Long Short Global Small Cap Fund LP acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 9,496 shares of the company's stock, valued at approximately $2,170,000.

Other hedge funds have also recently modified their holdings of the company. Chelsea Counsel Co. acquired a new position in shares of AbbVie during the third quarter valued at about $26,000. Westend Capital Management LLC acquired a new position in shares of AbbVie during the fourth quarter valued at about $29,000. Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie during the third quarter valued at about $31,000. WestEnd Advisors LLC increased its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. Finally, Caitlin John LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Insiders Place Their Bets

In related news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by company insiders.

AbbVie Price Performance

Shares of NYSE ABBV opened at $200.97 on Friday. The stock has a market capitalization of $355.34 billion, a price-to-earnings ratio of 85.15, a PEG ratio of 0.72 and a beta of 0.38. AbbVie Inc. has a 12 month low of $176.11 and a 12 month high of $244.81. The firm's 50 day simple moving average is $217.33 and its 200-day simple moving average is $222.62.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 EPS for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. The business had revenue of $16.62 billion for the quarter, compared to analysts' expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business's revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the company earned $2.16 EPS. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts anticipate that AbbVie Inc. will post 14.22 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.4%. AbbVie's dividend payout ratio (DPR) is currently 293.22%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie announced a $1.4 billion, 185‑acre advanced manufacturing campus in Durham, NC to produce immunology, neuroscience and oncology medicines; the investment is AbbVie’s largest single-site capital commitment and should support capacity, vertical integration and long‑term growth. AbbVie to build $1.4 billion manufacturing campus in North Carolina
• Positive Sentiment: Canaccord initiated coverage with a strong‑buy/Buy stance and a $262 price target, adding an analyst catalyst and incremental buy-side attention that may support near-term buying interest. AbbVie (ABBV): The Best Stock to Buy on a Pullback
• Positive Sentiment: AbbVie inked an exclusive licensing agreement with Haisco Pharmaceutical Group for pain‑medicine development, extending its pipeline and potential future product/IP upside. AbbVie Inc. (ABBV) Inks Licensing Agreement for Pain Medicines Development
• Neutral Sentiment: AbbVie is set to report Q1 2026 earnings on April 29; consensus estimates (Zacks) call for revenue around $14.78B and EPS near $2.69 — the print and management commentary could be a short‑term volatility trigger. AbbVie Q1 Earnings Loom: Buy or Sell the Stock Ahead of Results?
• Neutral Sentiment: Media and investor pieces highlighting AbbVie as a “buy on a pullback” or attractive dividend/biotech play add background interest but are not immediate catalysts without fresh fundamentals or trial readouts. AbbVie (ABBV): The Best Stock to Buy on a Pullback (InsiderMonkey)
• Negative Sentiment: The U.S. FDA has declined to approve AbbVie’s trenibotulinumtoxinE (TrenibotE) wrinkle treatment, citing manufacturing issues — that regulatory setback delays potential cosmetic-market revenue and introduces execution risk around manufacturing remediation. US FDA declines to approve AbbVie's wrinkle treatment (Reuters)
• Negative Sentiment: AbbVie confirmed receipt of a Complete Response Letter (CRL) from the FDA for the TrenibotE BLA related to manufacturing processes; while the agency did not request new clinical studies, fixing CMC (chemistry, manufacturing, controls) issues can be time‑consuming and costly. AbbVie Provides Update on TrenibotulinumtoxinE (TrenibotE) Biologics License Application in the U.S.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ABBV. UBS Group cut their target price on AbbVie from $240.00 to $230.00 and set a "neutral" rating on the stock in a research report on Thursday, February 5th. Wall Street Zen downgraded AbbVie from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 11th. Guggenheim upped their target price on AbbVie from $242.00 to $249.00 and gave the company a "buy" rating in a research report on Friday, April 10th. Royal Bank Of Canada began coverage on AbbVie in a research report on Tuesday, February 24th. They issued an "outperform" rating and a $260.00 target price on the stock. Finally, Barclays began coverage on shares of AbbVie in a report on Thursday, February 19th. They issued an "overweight" rating and a $275.00 price target on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $253.19.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.